These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 35054306)

  • 1. First Case of COVID-19 Treated with Monoclonal Anti-Spike Antibodies in a Patient with Cystic Fibrosis in Romania.
    Stan IV; Miron VD; Vangheli IA; Gheorghiu RM; Streinu-Cercel A; Săndulescu O; Craiu M
    Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies.
    Vellas C; Del Bello A; Gaube G; Tremeaux P; Jeanne N; Ranger N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac093. PubMed ID: 35299988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia.
    Phan AT; Gukasyan J; Arabian S; Wang S; Neeki MM
    Cureus; 2021 May; 13(5):e15280. PubMed ID: 34194882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of casirivimab/imdevimab in an intensive care unit patient with acute respiratory failure due to SARS-CoV-2 infection.
    Sloan B; Duhaime E; Sandkovsky U; Berhe M
    Proc (Bayl Univ Med Cent); 2022; 35(3):339-341. PubMed ID: 35518791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.
    Walicka-Serzysko K; Sands D
    Dev Period Med; 2015; 19(1):66-79. PubMed ID: 26003072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Casirivimab and Imdevimab for the Treatment of COVID-19.
    Liu R; Mangal R; Stead TS; Barbera AR; Ganti L
    Cureus; 2022 Aug; 14(8):e27766. PubMed ID: 36106219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Casirivimab-Imdevimab Antibody Cocktail in Patients Amidst and Post COVID 19 Treatment: A Retro-Prospective Comparative Study in India.
    Joy AP; Karattuthodi MS; Chandrasekher D; Augustine AT
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19.
    Bierle DM; Ganesh R; Wilker CG; Hanson SN; Moehnke DE; Jackson TA; Ramar P; Rosedahl JK; Philpot LM; Razonable RR
    J Prim Care Community Health; 2021; 12():21501327211019282. PubMed ID: 34032171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of casirivimab with imdevimab on disease progression in nonsevere COVID-19 patients in a single hospital in Japan.
    Komagamine J; Yabuki T; Yoshihara S; Tanaka N
    J Gen Fam Med; 2022 May; 23(3):158-163. PubMed ID: 35509339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center.
    Marwah V; Choudhary R; Adhikari S; Pemmaraju A; Menon AS; Manrai M; Ajai Kumar T; Verma S
    Med J Armed Forces India; 2023 May; ():. PubMed ID: 37360888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
    Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan.
    Osugi Y; Iwata H; Imai Y; Kobayashi D; Hirashima R
    Cureus; 2022 Feb; 14(2):e21882. PubMed ID: 35273850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro.
    Widera M; Wilhelm A; Hoehl S; Pallas C; Kohmer N; Wolf T; Rabenau HF; Corman VM; Drosten C; Vehreschild MJGT; Goetsch U; Gottschalk R; Ciesek S
    J Infect Dis; 2021 Oct; 224(7):1109-1114. PubMed ID: 34223909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 infection in a pediatric patient with cystic fibrosis.
    Páez-Velásquez JS; Romero-Uribe IE; Castilla-Peón MF; Lezana-Fernández JL; Chávez-López A
    Bol Med Hosp Infant Mex; 2021; 78(1):29-33. PubMed ID: 33661877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and treatment of cystic fibrosis. An update.
    Davis PB; di Sant'Agnese PA
    Chest; 1984 Jun; 85(6):802-9. PubMed ID: 6373170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis.
    Aanæs K
    J Cyst Fibros; 2013 Sep; 12 Suppl 2():S1-20. PubMed ID: 24064077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
    Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nocardia farcinica infection in a patient with cystic fibrosis].
    Beucher J; Belleguic C; Brinchault G; Deneuville E; Donnio PY; Roussey M
    Rev Mal Respir; 2010; 27(1):76-9. PubMed ID: 20146956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of failed eradication of cystic fibrosis-related sinus colonisation by Pseudomonas aeruginosa.
    Linnane B; Kearse L; O'Connell NH; Fenton J; Kiernan MG; Dunne CP
    BMC Pulm Med; 2015 Oct; 15():114. PubMed ID: 26445233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Functional endoscopic sinus surgery in a patient with cystic fibrosis after lung transplantation].
    Karpishchenko SA; Alekseenko SI; Kopylov VV; Baranskaya SV
    Vestn Otorinolaringol; 2021; 86(4):73-78. PubMed ID: 34499452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.